Skip to Content

Join the 'Alglucosidase Alfa' group to help and get support from people like you.

Alglucosidase Alfa News

FDA Expands Approval of Lumizyme to treat Pompe Disease Patients of All Ages

Posted 6 Aug 2014 by

August 1, 2014 – The U.S. Food and Drug Administration today announced the approval of Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than 8 years of age. In addition, the Risk Evaluation and Mitigation Strategy (REMS) known as the Lumizyme ACE (Alglucosidase Alfa Control and Education) Program is being eliminated. ...

Ask a Question

Further Information

Related Condition Support Groups

Pompe disease

Related Drug Support Groups

Lumizyme, Myozyme

Alglucosidase Alfa Patient Information at